The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Role of Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem-Cell Transplantation in Older Patients With De Novo Myelodysplastic Syndromes: An International Collaborative Decision Analysis
Open accessAbstract
Purpose: Myelodysplastic syndromes (MDS) are clonal hematopoietic disorders that are more common in patients aged ≥ 60 years and are incurable with conventional therapies. Reduced-intensity conditioning (RIC) allogeneic hematopoietic stem-cell transplantation is potentially curative but has additional mortality risk. We evaluated RIC transplantation versus nontransplantation therapies in older patients with MDS stratified by International Prognostic Scoring System (IPSS) risk. Patients and Methods: A Markov decision model with quality-of-life utility estimates for different MDS and transplantation states was assessed. Outcomes were life expectancy (LE) and quality-adjusted life expectancy (QALE). A total of 514 patients with de novo MDS aged 60 to 70 years were evaluated. Chronic myelomonocytic leukemia, isolated 5q– syndrome, unclassifiable, and therapy-related MDS were excluded. Transplantation using T-cell depletion or HLA-mismatched or umbilical cord donors was also excluded. RIC transplantation (n = 132) stratified by IPSS risk was compared with best supportive care for patients with nonanemic low/intermediate-1 IPSS (n = 123), hematopoietic growth factors for patients with anemic low/intermediate-1 IPSS (n = 94), and hypomethylating agents for patients with intermediate-2/high IPSS (n = 165). Results: For patients with low/intermediate-1 IPSS MDS, RIC transplantation LE was 38 months versus 77 months with nontransplantation approaches. QALE and sensitivity analysis did not favor RIC transplantation across plausible utility estimates. For intermediate-2/high IPSS MDS, RIC transplantation LE was 36 months versus 28 months for nontransplantation therapies. QALE and sensitivity analysis favored RIC transplantation across plausible utility estimates. Conclusion: For patients with de novo MDS aged 60 to 70 years, favored treatments vary with IPSS risk. For low/intermediate-1 IPSS, nontransplantation approaches are preferred. For intermediate-2/high IPSS, RIC transplantation offers overall and quality-adjusted survival benefit.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
International scoring system for evaluating prognosis in myelodysplastic syndromes
Greenberg, P., Cox, C., LeBeau, M. M., Fenaux, P., Morel, P., Sanz, G., Sanz, M., Vallespi, T., Hamblin, T., Oscier, D., et al. (1997) · Blood · doi:10.1182/blood.v89.6.2079 · Cited by 4,427
Self-citationProposals for the classification of the myelodysplastic syndromes
Bennett, J. M., Catovsky, D., Daniel, M. T., Flandrin, G., Galton, D. A. G., Gralnick, H. R., & Sultan, C. (1982) · British Journal of Haematology · doi:10.1111/j.1365-2141.1982.tb08475.x · Cited by 3,627
Harris, N. L., Jaffe, E. S., Diebold, J., Flandrin, G., Muller-Hermelink, H. K., Vardiman, J., Lister, T. A., & Bloomfield, C. D. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.12.3835 · Cited by 3,267
Revised International Prognostic Scoring System for Myelodysplastic Syndromes
Greenberg, P. L., Tuechler, H., Schanz, J., Sanz, G., Garcia-Manero, G., Solé, F., Bennett, J. M., Bowen, D., Fenaux, P., Dreyfus, F., et al. (2012) · Blood · doi:10.1182/blood-2012-03-420489 · Cited by 2,844
Self-citationFenaux, P., Mufti, G. J., Hellstrom-Lindberg, E., Santini, V., Finelli, C., Giagounidis, A., Schoch, R., Gattermann, N., Sanz, G., List, A., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70003-8 · Cited by 2,663
Self-citationClinical Effect of Point Mutations in Myelodysplastic Syndromes
Bejar, R., Stevenson, K., Abdel-Wahab, O., Galili, N., Nilsson, B., Garcia-Manero, G., Kantarjian, H., Raza, A., Levine, R. L., Neuberg, D., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1013343 · Cited by 1,627
Self-citation(2005) · Integrative Oncology · doi:10.1201/9780203088319-19 · Cited by 1,579
Kantarjian, H., Issa, J. J., Rosenfeld, C. S., Bennett, J. M., Albitar, M., DiPersio, J., Klimek, V., Slack, J., de Castro, C., Ravandi, F., et al. (2006) · Cancer · doi:10.1002/cncr.21792 · Cited by 1,530
Self-citationFischhoff, B. (1980) · Operations Research · doi:10.1287/opre.28.1.28 · Cited by 1,416
Proposals for the classification of the myelodysplastic syndromes
Bennett, J. M., Catovsky, D., Daniel, M., Flandrin, G., Galton, D. A. G., Gralnick, H. R., & Sultan, C. (1982) · British Journal of Haematology · doi:10.1111/j.1365-2141.1982.tb02771.x · Cited by 1,275
Malcovati, L., Germing, U., Kuendgen, A., Della Porta, M. G., Pascutto, C., Invernizzi, R., Giagounidis, A., Hildebrandt, B., Bernasconi, P., Knipp, S., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.5696 · Cited by 1,032
Self-citationMalcovati, L., Porta, M. G. D., Pascutto, C., Invernizzi, R., Boni, M., Travaglino, E., Passamonti, F., Arcaini, L., Maffioli, M., Bernasconi, P., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.7038 · Cited by 865
Self-citationHarris, N. L., Jaffe, E. S., Diebold, J., Flandrin, G., Muller-Hermelink, H. K., Vardiman, J., Lister, T. A., & Bloomfield, C. D. (1999) · Annals of Oncology · doi:10.1023/a:1008375931236 · Cited by 846
Cutler, C. S. (2004) · Blood · doi:10.1182/blood-2004-01-0338 · Cited by 673
Self-citationRollison, D. E., Howlader, N., Smith, M. T., Strom, S. S., Merritt, W. D., Ries, L. A., Edwards, B. K., & List, A. F. (2008) · Blood · doi:10.1182/blood-2008-01-134858 · Cited by 663
Silverman, L. R., McKenzie, D. R., Peterson, B. L., Holland, J. F., Backstrom, J. T., Beach, C. L., & Larson, R. A. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.4346 · Cited by 552
Self-citationMyelodysplastic syndromes: a scoring system with prognostic significance
Mufti, G. J., Stevens, J. R., Oscier, D. G., Hamblin, T. J., & Machin, D. (1985) · British Journal of Haematology · doi:10.1111/j.1365-2141.1985.tb07329.x · Cited by 507
McClune, B. L., Weisdorf, D. J., Pedersen, T. L., Tunes da Silva, G., Tallman, M. S., Sierra, J., DiPersio, J., Keating, A., Gale, R. P., George, B., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.4821 · Cited by 487
Self-citationFenaux, P., Giagounidis, A., Selleslag, D., Beyne-Rauzy, O., Mufti, G., Mittelman, M., Muus, P., te Boekhorst, P., Sanz, G., del Cañizo, C., et al. (2011) · Blood · doi:10.1182/blood-2011-01-330126 · Cited by 486
Self-citationRaza, A., Reeves, J. A., Feldman, E. J., Dewald, G. W., Bennett, J. M., Deeg, H. J., Dreisbach, L., Schiffer, C. A., Stone, R. M., Greenberg, P. L., et al. (2008) · Blood · doi:10.1182/blood-2007-01-068833 · Cited by 425
Self-citationSanz, G., Sanz, M., Vallespi, T., Canizo, M., Torrabadella, M., Garcia, S., Irriguible, D., & San Miguel, J. (1989) · Blood · doi:10.1182/blood.v74.1.395.395 · Cited by 406
Itzykson, R., Thépot, S., Quesnel, B., Dreyfus, F., Beyne-Rauzy, O., Turlure, P., Vey, N., Recher, C., Dartigeas, C., Legros, L., et al. (2011) · Blood · doi:10.1182/blood-2010-06-289280 · Cited by 383
Self-citationMyelodysplastic Syndromes — Coping with Ineffective Hematopoiesis
Cazzola, M., & Malcovati, L. (2005) · New England Journal of Medicine · doi:10.1056/nejmp048266 · Cited by 343
Self-citationPark, S., Grabar, S., Kelaidi, C., Beyne-Rauzy, O., Picard, F., Bardet, V., Coiteux, V., Leroux, G., Lepelley, P., Daniel, M.-T., et al. (2008) · Blood · doi:10.1182/blood-2007-06-096370 · Cited by 334
Self-citationJädersten, M., Malcovati, L., Dybedal, I., Giovanni Della Porta, M., Invernizzi, R., Montgomery, S. M., Pascutto, C., Porwit, A., Cazzola, M., & Hellström-Lindberg, E. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.4906 · Cited by 300
Self-citationMorel, P., Hebbar, M., Laï, J. L., Duhamel, A., Preudhomme, C., Wattel, E., Bauters, F., & Fenaux, P. (1993) · PubMed · Cited by 300
Self-citationGreenberg, P. L., Attar, E., Bennett, J. M., Bloomfield, C. D., De Castro, C. M., Deeg, H. J., Foran, J. M., Gaensler, K., Garcia-Manero, G., Gore, S. D., et al. (2011) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2011.0005 · Cited by 290
Self-citationDeeg, H. J., Storer, B., Slattery, J. T., Anasetti, C., Doney, K. C., Hansen, J. A., Kiem, H.-P., Martin, P. J., Petersdorf, E., Radich, J. P., et al. (2002) · Blood · doi:10.1182/blood-2002-02-0527 · Cited by 284
Self-citationBone marrow transplantation from HLA-identical siblings as treatment for myelodysplasia.
Sierra, J., Pérez, W. S., Rozmán, C., Carreras, E., Klein, J. P., Rizzo, J. D., Davies, S. M., Lazarus, H. M., Bredeson, C., Marks, D. I., et al. (2002) · PubMed · Cited by 269
Self-citationAul, C., Gattermann, N., Heyll, A., Germing, U., Derigs, G., & Schneider, W. (1992) · PubMed · Cited by 265
De Witte, T., Hermans, J., Vossen, J., Bacigalupo, A., Meloni, G., Jacobsen, N., Ruutu, T., Ljungman, P., Gratwohl, A., Runde, V., et al. (2000) · British Journal of Haematology · doi:10.1046/j.1365-2141.2000.02200.x · Cited by 251
Scott, B. L., Sandmaier, B. M., Storer, B., Maris, M. B., Sorror, M. L., Maloney, D. G., Chauncey, T. R., Storb, R., & Deeg, H. J. (2006) · Leukemia · doi:10.1038/sj.leu.2404010 · Cited by 235
Self-citationCastro-Malaspina, H., Harris, R. E., Gajewski, J., Ramsay, N., Collins, R., Dharan, B., King, R., & Deeg, H. J. (2002) · Blood · doi:10.1182/blood.v99.6.1943 · Cited by 227
Self-citationAlyea, E. P., Kim, H. T., Ho, V., Cutler, C., DeAngelo, D. J., Stone, R., Ritz, J., Antin, J. H., & Soiffer, R. J. (2006) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2006.06.003 · Cited by 186
Self-citationKantarjian, H. M., O'Brien, S. M., Shan, J., Aribi, A. M., Garcia‐Manero, G., Jabbour, E. J., Ravandi, F., Cortes, J. E., Davisson, J., & Issa, J. J. (2006) · Cancer · doi:10.1002/cncr.22376 · Cited by 115
Self-citationPlatzbecker, U., Schetelig, J., Finke, J., Trenschel, R., Scott, B. L., Kobbe, G., Schaefer‐Eckart, K., Bornhäuser, M., Itzykson, R., Germing, U., et al. (2012) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2012.05.003 · Cited by 94
Self-citationKoreth, J., Aldridge, J., Kim, H. T., Alyea, E. P., Cutler, C. S., Armand, P. A., Ritz, J., Antin, J. H., Soiffer, R. J., & Ho, V. T. (2010) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2009.12.537 · Cited by 81
Self-citationUnrelated Donor Bone Marrow Transplantation for Chronic Myelogenous Leukemia: A Decision Analysis
Lee, S. J., Kuntz, K. M., Horowitz, M. M., McGlave, P. B., Goldman, J. M., Sobocinski, K. A., Hegland, J., Kollman, C., Parsons, S. K., Weinstein, M. C., et al. (1997) · Annals of Internal Medicine · doi:10.7326/0003-4819-127-12-199712150-00005 · Cited by 81
Self-citationPorta, M. G. D., Jackson, C. H., Alessandrino, E. P., Rossi, M., Bacigalupo, A. P., Lint, M. T. V., Bernardi, M., Allione, B., Bosi, A., Guidi, S., et al. (2017) · Leukemia · doi:10.1038/leu.2017.88 · Cited by 76
Self-citationClinical Management of Myelodysplastic Syndromes With Interstitial Deletion of Chromosome 5q
Nimer, S. D. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.6715 · Cited by 56
Kurosawa, S., Yamaguchi, T., Miyawaki, S., Uchida, N., Kanamori, H., Usuki, K., Yamashita, T., Watanabe, M., Yakushiji, K., Yano, S., et al. (2010) · Blood · doi:10.1182/blood-2010-05-285502 · Cited by 50
Pan, F., Peng, S., Fleurence, R., Linnehan, J. E., Knopf, K., & Kim, E. J. (2010) · Clinical Therapeutics · doi:10.1016/j.clinthera.2010.12.003 · Cited by 33
Ng, A. K., Weeks, J. C., Mauch, P., & Kuntz, K. M. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.11.3577 · Cited by 25
Cited by
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia
Sperling, A. S., Gibson, C. J., & Ebert, B. L. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.112 · Cited by 678
Bejar, R., Stevenson, K. E., Caughey, B., Lindsley, R. C., Mar, B. G., Stojanov, P., Getz, G., Steensma, D. P., Ritz, J., Soiffer, R., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.52.3381 · Cited by 396
Self-citationAdès, L., Itzykson, R., & Fenaux, P. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61901-7 · Cited by 393
Self-citationde Witte, T., Bowen, D., Robin, M., Malcovati, L., Niederwieser, D., Yakoub-Agha, I., Mufti, G. J., Fenaux, P., Sanz, G., Martino, R., et al. (2017) · Blood · doi:10.1182/blood-2016-06-724500 · Cited by 379
Self-citation
Metadata
- Authors
- Koreth, J., Pidala, J., Perez, W. S., Deeg, H. J., Garcia-Manero, G., Malcovati, L., Cazzola, M., Park, S., Itzykson, R., Ades, L., Fenaux, P., Jadersten, M., Hellstrom-Lindberg, E., Gale, R. P., Beach, C. L., Lee, S. J., Horowitz, M. M., Greenberg, P. L., Tallman, M. S., DiPersio, J. F., Bunjes, D., Weisdorf, D. J., & Cutler, C.
- Venue
- Journal of Clinical Oncology
- Published
- 2013-07-20
- Volume
- 31
- Issue
- 21
- Pages
- 2662-2670
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2133682816
- Cited by
- 284
- References
- 43
- FWCI
- 20.90
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.